How to calculate number of events in each treatment arm given hazard ratio and CI?
|
|
2
|
3140
|
March 6, 2022
|
Covariate imbalance in RCT
|
|
5
|
4730
|
February 23, 2022
|
Estimate treatment effect in study with a composite complication score as outcome
|
|
9
|
2996
|
February 18, 2022
|
Single cluster cluster randomized crossover (CRXO) design?
|
|
3
|
2179
|
February 17, 2022
|
Bernoulli trials vs completely randomized trials
|
|
0
|
2556
|
January 5, 2022
|
Catastrophic Heterogeneity Meets "The Clairvoyant RCT"
|
|
0
|
2090
|
December 28, 2021
|
Cost-effectiveness based interim analysis
|
|
2
|
2872
|
December 15, 2021
|
Interpretation of the REGEN-COV trial
|
|
22
|
11065
|
November 1, 2021
|
First RCT of Lopinavir–Ritonavir on SARS-CoV2
|
|
38
|
18976
|
October 8, 2021
|
Extensions of 'worst-rank' score methods with outcomes truncated by death
|
|
13
|
3361
|
September 2, 2021
|
Resources for Mixed-Effect Models in Medical Contexts
|
|
7
|
3682
|
August 8, 2021
|
Heterogeneity in RCTs with continuous outcome
|
|
19
|
9929
|
July 2, 2021
|
Default Using R package to implement Bayesian phase I/II dose-finding design for three outcomes
|
|
10
|
4136
|
June 10, 2021
|
Multiplicity in clinical trials with hierarchical strategy
|
|
2
|
6475
|
December 30, 2020
|
RCT trials for COVID study vaccines
|
|
0
|
3209
|
October 24, 2020
|
Can treatment B be superior after the RCT if it was thought that treatment A is superior before the RCT?
|
|
5
|
3442
|
October 13, 2020
|
"Open label, double-masked trial"
|
|
0
|
3656
|
October 13, 2020
|
ANCOVA with randomized and nonrandomized groups
|
|
4
|
3564
|
September 30, 2020
|
Time since randomization and causality
|
|
2
|
2443
|
September 27, 2020
|
Bayesian Solutions for Challenges to Frequentist Statistics
|
|
0
|
5999
|
September 22, 2020
|
Empirical Bayes for RCT Interpretarion
|
|
8
|
5792
|
August 11, 2020
|
Re-starting a Bayesian group sequential design trial after stopping it
|
|
4
|
3096
|
August 11, 2020
|
MERINO trial - adjusting for infection source
|
|
3
|
5907
|
August 3, 2020
|
Thoughts on 'representativeness' and 'generalizability'
|
|
6
|
4540
|
July 19, 2020
|
Interpretation of INTERACT-2 Study in Intracerebral Hemorrhage
|
|
3
|
5375
|
June 15, 2020
|
Open-label RCT of triple combination (LPV/r, Ribavirin, Interferon) on SARS-CoV2
|
|
1
|
3256
|
May 15, 2020
|
Type I error in a specific design of 2-parallel group study
|
|
3
|
3949
|
March 11, 2020
|
RCT generalizability and interactions with treatment
|
|
8
|
5132
|
March 10, 2020
|
Presenting models of multiple (potentially recurring) outcomes
|
|
1
|
3959
|
March 6, 2020
|
Power for interaction effects
|
|
6
|
5150
|
February 24, 2020
|